India's Piramal Pharma rises on UK nod for drug to treat hypotension in infants

Piramal Pharma (Mumbai)

21/03/2025 05:36

** Shares of Piramal Pharma PIRM.NS rise 2.5% to 227 rupees apiece

** Pharma company's unit gets market authorization from UK's drug regulator for the use of its drug formulation to treat hypotension in neonates, infants and children

** With this, PIRM has secured commercialization rights for the drug Neoatricon for the European Union, the UK and Norway

** PIRM is down 15% in 2025 compared to a 14% fall in the small-cap 100 index .NIFSMCP100, of which it is a constituent

(Reporting by Bharath Rajeswaran in Bengaluru)

((bharath.rajeswaran@thomsonreuters.com; +91 9769003463;))